Creative Planning Sells 600 Shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI)

Creative Planning cut its position in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 2.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 29,740 shares of the company’s stock after selling 600 shares during the period. Creative Planning owned approximately 0.06% of Aerie Pharmaceuticals worth $572,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in AERI. BlackRock Inc. boosted its stake in Aerie Pharmaceuticals by 11.0% during the second quarter. BlackRock Inc. now owns 3,358,901 shares of the company’s stock valued at $99,255,000 after buying an additional 331,884 shares during the last quarter. C WorldWide Group Holding A S boosted its stake in Aerie Pharmaceuticals by 235.0% during the second quarter. C WorldWide Group Holding A S now owns 456,142 shares of the company’s stock valued at $13,479,000 after buying an additional 320,000 shares during the last quarter. Waddell & Reed Financial Inc. boosted its stake in Aerie Pharmaceuticals by 14.8% during the second quarter. Waddell & Reed Financial Inc. now owns 1,737,627 shares of the company’s stock valued at $51,347,000 after buying an additional 224,655 shares during the last quarter. Bamco Inc. NY boosted its stake in Aerie Pharmaceuticals by 400.7% during the second quarter. Bamco Inc. NY now owns 275,226 shares of the company’s stock valued at $8,133,000 after buying an additional 220,263 shares during the last quarter. Finally, Rhenman & Partners Asset Management AB boosted its stake in Aerie Pharmaceuticals by 82.7% during the third quarter. Rhenman & Partners Asset Management AB now owns 475,000 shares of the company’s stock valued at $9,130,000 after buying an additional 215,000 shares during the last quarter.

In other Aerie Pharmaceuticals news, major shareholder Foresite Capital Fund Ii, L.P. purchased 46,153 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was purchased at an average cost of $23.45 per share, with a total value of $1,082,287.85. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Vicente Anido, Jr. purchased 26,250 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were acquired at an average cost of $19.01 per share, with a total value of $499,012.50. Following the completion of the purchase, the chief executive officer now directly owns 195,631 shares in the company, valued at approximately $3,718,945.31. The disclosure for this purchase can be found here. Insiders have purchased a total of 273,143 shares of company stock valued at $6,085,038 over the last three months. 8.71% of the stock is owned by corporate insiders.

NASDAQ:AERI opened at $18.80 on Thursday. Aerie Pharmaceuticals Inc has a 1 year low of $17.51 and a 1 year high of $50.10. The business has a 50 day simple moving average of $20.68 and a 200-day simple moving average of $26.98. The company has a quick ratio of 5.23, a current ratio of 5.43 and a debt-to-equity ratio of 0.94.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.02). Aerie Pharmaceuticals had a negative net margin of 328.34% and a negative return on equity of 77.63%. The company had revenue of $18.54 million during the quarter, compared to the consensus estimate of $17.59 million. Research analysts anticipate that Aerie Pharmaceuticals Inc will post -3.77 EPS for the current fiscal year.

A number of equities analysts recently commented on the company. Oppenheimer dropped their price target on Aerie Pharmaceuticals from $45.00 to $25.00 in a research note on Thursday, November 7th. Cantor Fitzgerald dropped their price target on Aerie Pharmaceuticals from $62.00 to $30.00 and set an “overweight” rating for the company in a research note on Thursday, November 7th. JMP Securities lowered their price objective on Aerie Pharmaceuticals to $41.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Piper Jaffray Companies lowered their price objective on Aerie Pharmaceuticals from $53.00 to $48.00 and set an “overweight” rating for the company in a research note on Thursday, November 7th. Finally, BidaskClub raised Aerie Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 30th. One analyst has rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the company’s stock. Aerie Pharmaceuticals has an average rating of “Buy” and an average target price of $43.33.

Aerie Pharmaceuticals Profile

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Further Reading: How is Preferred Stock Different from Common Stock?

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.